How Does an RSV Monoclonal Antibody Protect Infants?

RSV monoclonal antibodies are lab-made proteins designed to protect infants from respiratory syncytial virus, a pathogen responsible for roughly 33 million lower respiratory infections in children under five each year worldwide. Unlike traditional vaccines, which train the immune system to build its own defenses, these antibodies arrive ready-made and start neutralizing the virus immediately after a single injection. The first product, palivizumab, has been available since the late 1990s but was restricted to high-risk babies. A newer antibody called nirsevimab changed the landscape by offering protection to all infants with one shot lasting an entire RSV season, and another candidate, clesrovimab, is moving through late-stage trials. The science behind these products, how well they perform outside clinical trials, and where the field is headed all deserve a closer look.

Why RSV Matters So Much for Infants

Almost every child catches RSV by age two. For most, it causes cold-like symptoms. For a significant minority, it triggers bronchiolitis or pneumonia that can land a baby in the hospital. A 2019 global burden study estimated about 3.6 million RSV-related hospital admissions and over 100,000 deaths in children under five, with nearly half of those deaths occurring in infants younger than six months.¹ Babies in that youngest age window are especially vulnerable because their immune systems are immature and their airways are tiny. Until recently, there were no effective preventive treatments available for the vast majority of healthy infants.²

How Monoclonal Antibodies Work Against RSV

RSV enters airway cells by using a surface protein called the fusion (F) protein, which changes shape to fuse the virus’s outer envelope with the cell membrane. Monoclonal antibodies work by locking onto the F protein and physically blocking that shape change so the virus cannot get inside cells. The critical insight that drove the newer generation of antibodies was recognizing that the F protein in its “prefusion” shape, the form it takes before it merges with a cell, is the main target of the body’s most potent neutralizing response. Researchers found that antibodies directed at this prefusion form were substantially more potent than the older antibody palivizumab.³

Potency alone, though, does not solve the problem for infants. Normal antibodies are cleared from the blood within a few weeks. To cover an entire RSV season of roughly five months, nirsevimab was engineered with specific modifications to its structural backbone that extend its half-life in the bloodstream to about 71 days, roughly three times longer than a standard antibody. That engineering is what makes a single intramuscular injection sufficient for a full season of protection.⁴

Palivizumab and Its Limitations

Palivizumab, approved in 1998, proved that passive immunization with a monoclonal antibody could reduce RSV hospitalizations in high-risk children.⁵ It was a genuine advance, but it came with serious practical drawbacks. The drug requires monthly injections throughout RSV season, typically five doses, and it carries a high price tag that restricted its use to premature infants, babies with chronic lung disease, or those with certain heart conditions. Even in those groups, while palivizumab reduced hospitalizations, it was never shown to reduce deaths, length of hospital stays, or other serious complications.⁶ Its cost-effectiveness was documented for the most common high-risk indications during a baby’s first RSV season, but using it universally was never economically realistic.⁷

Nirsevimab in Clinical Trials

Nirsevimab was the first monoclonal antibody designed to protect all infants, not just those at high risk. In a pivotal trial involving healthy late-preterm and term infants, a single injection before RSV season cut medically attended RSV lower respiratory tract infections by about 75% compared with placebo.⁸ A pooled analysis combining data from multiple trials showed a roughly 80% reduction in medically attended RSV lower respiratory infections, a 77% reduction in RSV-related hospitalizations, and an 86% reduction in very severe RSV disease.⁹

Those numbers looked strong, but clinical trials happen under controlled conditions with carefully selected participants. The real test was always going to be what happened once countries started rolling out the drug to every newborn walking out of a hospital.

Real-World Performance

The early real-world data has been reassuring. A systematic review and meta-analysis of observational studies found that nirsevimab was associated with about an 83% lower odds of RSV-related hospitalization and an 81% lower odds of ICU admission in infants under 12 months.¹⁰ A separate living systematic review estimated roughly 81% effectiveness against RSV-related emergency department visits and about 76% against ICU admissions.¹¹

France was one of the first countries to launch a national nirsevimab immunization campaign for infants. During that first season, the drug showed 83% effectiveness against emergency department visits for RSV-associated bronchiolitis and 83% against RSV-related hospitalizations. Protection was even higher against the most severe outcomes, with about 91% effectiveness against hospitalizations needing supplemental oxygen.¹² These numbers track closely with the clinical trial results, which is not always the case with new drugs entering messy, real-world conditions.

What About High-Risk Babies Specifically

Nirsevimab was designed to be universal, but parents and clinicians naturally want to know how it performs in the babies who are most vulnerable: extremely premature infants, those with congenital heart disease, and those with chronic lung disease. In pharmacokinetic studies, nirsevimab maintained adequate blood levels in more than 80% of these high-risk populations, suggesting the standard dose is sufficient for most.¹³

Real-world data from a recent study painted a slightly more nuanced picture. Among all at-risk infants, nirsevimab was associated with about an 84% reduction in RSV-related hospitalizations. Infants with congenital heart disease saw an even higher estimated reduction of about 96%. However, among infants born extremely premature, the point estimate for protection was lower at about 66%, and the confidence interval was wide enough that a true zero effect could not be ruled out statistically.¹⁴ That does not mean the drug fails in very premature babies. It likely still helps. But this population may need more attention and possibly adjusted dosing or additional protective strategies in the future.

Clesrovimab and the Next Wave

Nirsevimab is not the only long-acting RSV antibody in development. Clesrovimab, which targets a different spot on the RSV fusion protein (site IV rather than site Ø), has completed a large phase 3 trial. Through 150 days after injection, clesrovimab reduced medically attended RSV lower respiratory infections by about 60% compared with placebo and reduced RSV-related hospitalizations by about 84%.¹⁵ Earlier-phase trials had already shown the drug was well tolerated and maintained an extended half-life compared to standard antibodies.¹⁶

Having two antibodies targeting different sites on the same protein matters beyond just market competition. If the virus ever evolves resistance to one antibody’s binding site, an alternative that binds elsewhere would remain effective. Targeting separate epitopes also opens the door to combination strategies down the road.

How Monoclonal Antibodies Compare With Maternal Vaccination

Since 2023, a maternal RSV vaccine has also been available, given to pregnant people in the third trimester so that protective antibodies pass to the baby before birth. Both approaches deliver passive immunity to the newborn, but they differ in important ways. Modeling work comparing the two strategies found that while maternal vaccination produces high neutralizing antibody levels at birth, those antibodies decline faster than those from a direct injection of a long-acting monoclonal antibody. By about three months of age, antibody levels from maternal vaccination had already dropped below those from passive immunization, and the gap widened from that point onward.¹⁷

This matters practically because RSV hospitalizations peak between two and four months of age. Maternal vaccination provides excellent early coverage, but the monoclonal antibody offers a longer tail of protection. Both strategies have their place, and the best choice for a given infant depends on timing of birth relative to RSV season, whether the mother received the vaccine during pregnancy, and local availability.

Will RSV Mutate Around These Antibodies

Any time you put evolutionary pressure on a pathogen by deploying a drug that blocks it, there is a legitimate question about resistance. The good news is that the RSV fusion protein is far more genetically stable than, say, the influenza hemagglutinin or the SARS-CoV-2 spike protein. A bioinformatics analysis of over 3,600 RSV fusion protein sequences collected between 1956 and 2021 found that nearly all amino acid positions within the nirsevimab binding site remained highly conserved, and variants with reduced susceptibility to nirsevimab were detected at very low frequencies, below 1%.¹⁸

A German pediatric cohort study conducted before widespread nirsevimab use looked specifically for pre-existing resistance mutations. In RSV-A strains, known resistance mutations were essentially absent. In RSV-B strains, the most common variants in the binding region actually had no negative effect on nirsevimab’s effectiveness, and one common variant combination even increased the virus’s susceptibility to the drug. The one mutation known to reduce susceptibility, K68N, was found in a single sample out of the entire cohort.¹⁹ Ongoing surveillance will be essential as millions of doses are administered each season, but the starting position is favorable.

Practical Challenges of Rolling Out a New Product

A drug that works in trials and works in the real world still faces a gauntlet of logistical challenges when you try to give it to every newborn in a country. The first RSV season after nirsevimab’s approval in the United States (2023-2024) was a case study in what can go wrong. Hospitals had a short window between the drug’s approval and RSV season to build clinical protocols, train staff, educate parents, and sort out billing and reimbursement. Then a supply shortage hit partway through the season, forcing the CDC to issue emergency guidance prioritizing the highest-risk infants. On top of that, some parents were hesitant about a novel product, and documentation of maternal vaccination status was inconsistent, making it harder to decide which babies still needed the antibody.²⁰

Ontario’s first-season experience was similar. A post-season review by healthcare providers involved in the province’s program identified governance, funding, distribution logistics, public awareness, and surveillance as the five pillars that needed strengthening for future seasons.²¹ These problems are solvable, and second-season implementation should be smoother. But they underscore that getting an effective drug from lab to arm involves far more than the science.

Can Monoclonal Antibodies Be Given Alongside Routine Vaccines

Parents sometimes worry that giving an RSV monoclonal antibody at the same time as routine childhood vaccines could interfere with the infant’s immune responses to those vaccines. The evidence says otherwise. Palivizumab has been co-administered with routine pediatric vaccines for over two decades without safety signals or any indication it blunts the immune response to other shots. Because monoclonal antibodies like nirsevimab target a single viral protein and do not engage the broader immune machinery the way a vaccine does, immunization guidelines from major advisory bodies support giving them at the same clinic visit as standard childhood vaccines.²² This is a practical advantage because it eliminates the need for extra clinic visits.

Cost and Access in Low-Income Settings

The burden of RSV falls hardest on low- and middle-income countries, where most RSV deaths occur. Palivizumab was never a realistic option for these settings because of its cost and the logistical difficulty of delivering five monthly injections. Long-acting monoclonal antibodies like nirsevimab, requiring just one dose, are far more practical. Economic modeling has generally found that long-acting infant monoclonal antibodies are likely cost-effective, with incremental cost-effectiveness ratios in low- and middle-income settings estimated in the range of roughly $460 to $3,000 per disability-adjusted life year averted.²³ Those figures compare favorably to many established public health interventions. Still, making these products affordable and deliverable through existing immunization programs in resource-limited settings will require coordination between maternal and child health systems and national immunization programs.²⁴

Why a Vaccine Took So Long and Why Antibodies Came First

The history matters here because it explains why the monoclonal antibody approach was not just a stopgap but a strategic necessity. In the 1960s, a formalin-inactivated RSV vaccine was tested in infants and toddlers. Instead of protecting them, it caused a paradoxical worsening of disease when vaccinated children later caught natural RSV. Hospitalizations were frequent, and two toddlers died. Decades of research eventually showed that the inactivated vaccine had primed the immune system to produce non-protective antibodies and an inflammatory T-cell response without generating the cytotoxic immune cells needed to actually clear the virus.²⁵

That disaster hung over the field for decades, making regulators and researchers deeply cautious about any RSV vaccine for young children. Monoclonal antibodies neatly sidestep the problem. They do not activate the infant’s own immune system at all. They simply provide ready-made neutralizing proteins that block the virus and then gradually clear from the body. There is no immune memory formed, no risk of the harmful immune priming that doomed the 1960s vaccine. This is also why monoclonal antibodies need to be given every season: they do not teach the immune system anything lasting.

Open Questions and Ongoing Research

Several important questions remain unanswered. One is whether preventing severe RSV infections in infancy might reduce the risk of asthma later in childhood, a connection that epidemiological studies have long hinted at. Another is whether repeat dosing across multiple RSV seasons is necessary or safe; most data so far covers a single season for each infant. There are also active investigations into whether these antibodies could benefit high-risk adults, including immunocompromised patients such as transplant recipients or people on chemotherapy, populations where RSV can be dangerous and treatment options remain limited.²⁶ Palivizumab has been explored as prophylaxis in adult immunocompromised patients, though data in that group remain thin.²⁷ Deep mutational scanning work is also mapping the landscape of possible RSV F protein mutations to understand which changes the virus could make while still remaining functional, and how each mutation might affect neutralization by nirsevimab, clesrovimab, and other antibodies in development.²⁸ That kind of preemptive mapping could help scientists stay ahead of any resistance that does emerge, rather than reacting to it after the fact.